# TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB

> **NCT00664313** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 36 (actual)

## Conditions studied

- Multi-drug Resistant Tuberculosis
- Extensively Drug Resistant Tuberculosis

## Interventions

- **DRUG:** Linezolid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00664313
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664313, "TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00664313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*